Balversa

Active Ingredient(s): Erdafitinib
FDA Approved: * April 12, 2019
Pharm Company: * JANSSEN BIOTECH
Category: Cancer

Erdafitinib, sold under the brand name Balversa, is an anti-cancer medication. It is a small molecule inhibitor of fibroblast growth factor receptor (FGFR) used for the treatment of cancer. FGFRs are a subset of tyrosine kinases which are unregulated in some tumors and influence tumor cell differentiation, proliferation, angiogenesis, and cell survival.[1][2] Astex Pharmaceuticals discovered the drug and licensed it to Janssen Pharmaceuticals for further develo... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Balversa 3 mg Oral Tablet, Film Coated
NDC: 59676-030
Labeler:
Janssen Products Lp
Balversa 4 mg Oral Tablet, Film Coated
NDC: 59676-040
Labeler:
Janssen Products Lp
Balversa 5 mg Oral Tablet, Film Coated
NDC: 59676-050
Labeler:
Janssen Products Lp